<DOC>
	<DOCNO>NCT02261064</DOCNO>
	<brief_summary>Study investigate relative bioavailability pharmacokinetics fixed-dose combination tablet ( telmisartan 40 mg/amlodipine 5 mg telmisartan 80 mg/amlodipine 5 mg ) feed condition compare fixed-dose combination fast condition healthy Japanese male volunteer .</brief_summary>
	<brief_title>Influence Food Bioavailability Telmisartan/Amlodipine Fixed Dose Combination Healthy Japanese Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>1 . Healthy male volunteer without clinically significant finding complication basis complete medical history , include physical examination , vital sign ( blood pressure , pulse rate , body temperature ) , 12lead electrocardiogram ( ECGs ) , clinical laboratory test 2 . Age : ≥20 Age ≤35 year 3 . Body weight : ≥50 kg 4 . Body mass index ( BMI ) : ≥18.0 ≤25.0 kg/m2 5 . Signed date write informed consent prior admission trial accordance Good Clinical Practice ( GCP ) local legislation 1 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological , hormonal disorder 2 . Diseases central nervous system ( epilepsy ) psychiatric neurological disorder 3 . Chronic relevant acute infection 4 . Any clinical relevant finding laboratory test result deviate normal 5 . A positive result hepatitis B surface antigen ( HBsAg ) , antihepatitis C virus ( HCV ) antibody , syphilitic test , human immunodeficiency virus ( HIV ) test 6 . History surgery gastrointestinal tract ( except appendectomy ) 7 . History relevant orthostatic hypotension , faint spell , blackouts 8 . Known hypersensitivity component formulation ( telmisartan amlodipine ) , angiotensin II receptor blocker , dihydropyridine compound 9 . Intake drug long halflife ( ≥24 hour ) within least 1 month less 10 halflives respective drug drug administration 10 . Intake drug might reasonably influence result trial basis knowledge time protocol preparation within 7 day drug administration 11 . Participation another trial investigational drug within 4 month 6 halflives investigational product drug administration 12 . Smoker ( ≥20 cigarettes/day ) 13 . Alcohol abuse ( 60 g ethanol/day : e.g. , 3 middlesized bottle beer , 3 gous [ equivalent 540 mL ] sake ) 14 . Drug abuse 15 . Blood donation ( 100 mL within 4 week drug administration ) 16 . Excessive physical activity ( within 1 week drug administration ) 17 . Intake alcohol within 2 day drug administration 18 . Inability comply dietary regimen study centre 19 . Inability refrain smoke trial day 20 . Subjects judge inappropriate investigator subinvestigator</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>